<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> <z:hpo ids='HP_0002835'>aspiration</z:hpo> (TA) has been shown to improve microvascular perfusion during primary percutaneous coronary intervention (PCI) for patients with ST-segment elevation <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of our study was to assess the relationship between TA and myocardial <z:hpo ids='HP_0000969'>edema</z:hpo>, myocardial <z:mp ids='MP_0001914'>hemorrhage</z:mp>, microvascular obstruction (MVO) and left ventricular remodeling in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e> patients using cardiovascular magnetic resonance (CMR) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Sixty patients were enrolled post primary PCI and underwent CMR on a 1.5 T scanner at 48 hours and 6 months </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were retrospectively stratified into 2 groups: those that received TA (35 patients) versus that did not receive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> <z:hpo ids='HP_0002835'>aspiration</z:hpo> (<z:chebi fb="0" ids="39054">NTA</z:chebi>) (25 patients) </plain></SENT>
<SENT sid="4" pm="."><plain>Myocardial <z:hpo ids='HP_0000969'>edema</z:hpo> and myocardial <z:mp ids='MP_0001914'>hemorrhage</z:mp> were assessed by T2 and T2* quantification respectively </plain></SENT>
<SENT sid="5" pm="."><plain>MVO was assessed via a contrast-enhanced T1-weighted inversion recovery gradient-echo sequence </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: At 48 hours, <z:mpath ids='MPATH_124'>infarct</z:mpath> segment T2 (<z:chebi fb="0" ids="39054">NTA</z:chebi> 57.9 ms vs. TA 52.1 ms, p = 0.022) was lower in the TA group </plain></SENT>
<SENT sid="7" pm="."><plain>Also, <z:mpath ids='MPATH_124'>infarct</z:mpath> segment T2* was higher in the TA group (<z:chebi fb="0" ids="39054">NTA</z:chebi> 29.3 ms vs. TA 37.8 ms, p = 0.007) </plain></SENT>
<SENT sid="8" pm="."><plain>MVO incidence was lower in the TA group (<z:chebi fb="0" ids="39054">NTA</z:chebi> 88% vs. TA 54%, p = 0.013).At 6 months, left ventricular end-diastolic volume index (<z:chebi fb="0" ids="39054">NTA</z:chebi> 91.9 ml/m2 vs. TA 68.3 ml/m2, p = 0.013) and left ventricular end systolic volume index (<z:chebi fb="0" ids="39054">NTA</z:chebi> 52.1 ml/m2 vs. TA 32.4 ml/m2, p = 0.008) were lower and <z:mpath ids='MPATH_124'>infarct</z:mpath> segment systolic wall thickening was higher in the TA group (<z:chebi fb="0" ids="39054">NTA</z:chebi> 3.5% vs. TA 74.8%, p = 0.003) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: TA during primary PCI is associated with reduced myocardial <z:hpo ids='HP_0000969'>edema</z:hpo>, myocardial <z:mp ids='MP_0001914'>hemorrhage</z:mp>, left ventricular remodeling and incidence of MVO after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e> </plain></SENT>
</text></document>